Home » Newsletters » BioWorld Science

BioWorld Science

May 23, 2014

View Archived Issues

Toxin-specific MAbs show efficacy in hamster model of CDAD

Urothelial carcinogen resistance model developed in rats

Interferon alpha inhibitor shows promise for the treatment of HIV encephalitis

Daiichi Sankyo recaps events of fourth quarter of fiscal 2013

Neurotrope and Stanford University collaborate on bryologs

Russian and U.S. researchers design new antibodies for HCV infection

Ensemble Therapeutics presents novel IL-17R modulators

Novel azithromycin derivative identified for pulmonary inflammation

Sanofi divulges novel P2Y12 receptor antagonists for thrombotic disorders

RedHill Biopharma and IntelGenx report promising RHB-103 bioavailability data

Adamas Pharmaceuticals receives milestone payment from Forest Laboratories

FDA grants orphan drug status to retinitis pigmentosa treatment candidate

IBI-302 investigated for AMD in vitro and in vivo

NIH funding to support Cognition Therapeutics' work in Alzheimer's disease

Oral fenretinide studied in new phase I trial in cystic fibrosis

WILEX and UCB terminate oncology collaboration

Gedeon Richter to buy majority stake in marketing company Mediplus

Empagliflozin evaluated in patients with diabetes and hypertension in phase III trials

CHMP issues positive opinion for Envarsus in kidney and liver transplant patients

Janssen withdraws application for intravenously administered Simponi in E.U.

Lanthio Pharma receives Dutch government loan to develop novel therapy for lung fibrosis

Avipero and Fusion Antibodies collaborate to humanize integrin antibodies

Sanford-Burnham and Daiichi Sankyo collaborate in cardiovascular-metabolic diseases

Neurotez and GCA Therapeutics sign Chinese license agreement for leptin derivatives

FDA extends Zerenex PDUFA goal date

Nuvilex initiates preclinical studies targeting pancreatic cancer pain and ascites

Empagliflozin approved in E.U.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
Cancer specter looming, Abtect effect in UC wallops Abivax
BioWorld
Although analysts liked the data – calling them “truly amazing” and “transformational” – Wall Street apparently had qualms about three cancer cases that turned up...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC
BioWorld Science
At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...